

Please amend claims 14 and 16.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-13. (Cancelled)

14. (Currently Amended) A composition for preventing enhanced promotion of neuronal-cell-death survival, comprising a neurotrophin and a tetrafluorobenzyl derivative 5-benzyloaminosalicylic acid, 5-(4-trifluoromethylbenzyl) aminosalicylic acid, 5-(4-nitrobenzyl) aminosalicylic acid, 5-(4-chlorobenzyl) aminosalicylic acid, 5-(4-methoxybenzyl) aminosalicylic acid, 5-(4-fluorobenzyl) aminosalicylic acid, or 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid.

15. (Previously Presented) The composition according to claim 14 wherein the neurotrophin is selected from nerve growth factor, brain-derived neurotrophic factor, neurotrophin-3 and neurotrophin-4/5.

16. (Currently Amended) The composition according to claim 14 wherein the tetrafluorobenzyl derivative is composition comprises a neurotrophin and 2-Hhydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid.

17. (Previously Presented) The composition according to claim 14, further including a pharmaceutical carrier.